Abstract
Purpose :
Non -total invasive method to administer antiVEGF in the posterior segment of the eye
Methods :
After experimentations on pig eyes and in consideration of the excellent correspondence with the human eye , we subjected 21 voluntary patients with macular CNV to transcleral iontophoresis with bevacizumav..
All patients were at the second recurrence therapy in the same eye so that the comparision parameters( BCVA,mycroperimeter,OCT, multifocal ERG)were similar.
We made a subconjuntivasl injection of bevacizumav and carried out 10 microampere per square centimeter of iontophoresis for 20 minutes.
Results :
BCVA, mycroperimeter , OCT, mERG were without significant differences (p<0.1) were similar to the previous one for all patients but compliance was much better ( satisfation card )
In Italy the administration of antiVEGF is normally performed in the surgery theatre while this treatment can be performed in tha outpatient department generating lower cost.
Conclusions :
Anodic ionophoresis promotes transcleral transport of bevacizumav not subject to electromagnetic rejection.
In fact the sclera is a porosa membrane that is charged negatively at pH above 5 and the bevacizumav is a neutral compound .
So we get undeniable advantage due to better patient avaiability, lower cost, lower risk ( endophthalmitis ..)
In our knowledge this is the first time that the ionophoresis can be used in this field .
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.